Related Experiment Video
Updated: Aug 8, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
Clinical pharmacodynamics of quinolones
Paul G Ambrose1, Sujata M Bhavnani, Robert C Owens
1Division of Infectious Diseases, Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA. paul.ambrose@cognigencorp.com
Abstract:
An understanding of fundamental PK-PD principles forms the basis for the rational use of antimicrobial agents. For quinolones, the fAUC24:MIC ratio is predictive of efficacy in animal and in vitro infection models, and in infected patients. The magnitude of the fAUC24:MIC ratio predictive of efficacy in animal and in vitro infection models has been shown to be concordant with those obtained from human data. By accounting for PK and microbiologic variability together with PK-PD targets associated with efficacy or resistance suppression by Monte Carlo simulation, it is possible to discriminate between therapeutic regimens and select those regimens likely to be of greater benefit to patients. The maturation of antimicrobial PK-PD as a scientific discipline continues to accelerate and currently impacts clinical practice, drug development, and regulatory decision making.
More Related Videos
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Linear Concentration–Effect Model
Inhibitors of Bacterial DNA Synthesis

